Abstract:Background: A statin alone or non-statins as add-ons have been introduced to intensive low-density lipoprotein cholesterol (LDL-C) -lowering therapy in patients at risk for high cardiovascular disease (CVD). The purpose of this study was to evaluate the effectiveness and safety of different rosuvastatin-based regimens for patients at high risk. Methods: Three hundred patients at high CVD risk were randomly assigned to the statin group (rosuvastatin, 20 mg/d), statin_EZ group (statin 10 mg/d + ezetimibe 10 mg/d), statin_pcsk group (statin 10 mg/d + alirocumab 75 mg/2 weeks) or combine3 group (statin 10 mg/d + ezetimibe 10 mg/d + alirocumab 75 mg/2 weeks). The primary outcome measure was cholesterol levels after 24 weeks of follow-up. Secondary outcomes included safety markers and the proportion of patients achieving the 70 mg/dL (1.8 mmol/L) target for LDL-C. A logistic regression model was performed to explore the factors affecting lipid target achievement. Results: The total cholesterol (TC) and LDL-C levels in the four groups after treatment were significantly lower than those before treatment. TC and LDL-C levels after treatment were significantly different among the four groups (p < 0.05). The levels in both the combine3 and statin_pcsk9 groups were significantly lower than those in the statin and statin_EZ groups (p < 0.05), but there was no significant difference between the combine3 and statin_pcsk9 groups. Fifty-one participants (69%) in the statin_pcsk9 group and 56 participants (78%) in the combine3 group achieved the target. Body mass index (BMI) and hypertensive status were related to LDL-C target achievement. The incidence of adverse events in the four groups was low. Conclusions: The combination of a statin and a PCSK9 inhibitor was safe and more effective for the treatment of high-risk CVD patients, while the addition of ezetimibe was unable to significantly lower lipid levels any further. The rate of achieving the target was higher in patients with hypertension and a low BMI. Clinical trial registration: Chinese Clinical Trial Registry, Identifier: ChiCTR2200058389, Date of Registration: 2022-04-08.

The Effects of Atorvastatin and Rosuvastatin on Exercise Tolerance in Patients with Coronary Heart Disease

Effect of atorvastatin on decreasing a hypertensive response to exercise and improving exercise tolerance

Effect of atorvastatin on exercise tolerance in patients with diastolic dysfunction and exercise-induced hypertension

Effect of statin on improves cardiac diastolic function and reduces exercise B-type natriuretic peptide level

Clinical Study for Dose-Effect and Safety of Rosuvastatin in Patients with Primary Hypercholesterolemia

Effects of Different Doses of Rosuvastatin on High-sensitivity C-reactive Protein(hs-CRP) and Interleukin-6 (IL-6) in Patients with Acute Coronary Syndrome.

Comparing the Effect of Combining Exercise with Rosuvastatin versus Atorvastatin on Lipid Profile and Functional Capacity: A Retrospective Cohort Study

Comparison Between Atorvastatin and Rosuvastatin on Secondary Percutaneous Coronary Intervention Rate and the Risk Factors in Patients with Coronary Heart Disease.

[Effects of Aerobic Exercise on Exercise Tolerance in Patients with Chronic Heart Failure].

Effect of Atorvastatin Versus Rosuvastatin on Levels of Serum Lipids, Inflammatory Markers and Adiponectin in Patients with Hypercholesterolemia

Comparison of efficacy of rosuvastatin and artovastatin in treatment of hypercholesterolemia

Effect of Rosuvastatin on Left Ventricular Function in Hypertensive Patients

Effects of Atorvastatin on Patients with Coronary Heart Disease after Percutaneous Coronary Intervention

Effects Of Different Doses Of Atorvastatin On Blood Lipids, Cardiac Function And Prognosis In Elderly Patients With Acute Myocardial Infarction

Effects of atorvastatin on left ventricular function in old patients with serious-ischemic coronary artery disease

The Effect of Rosuvastatin and Atrovastatin on Plasma Lipoprotein-Associated Phospholipase A2 Activity in Patients with Hypercholesterolemia

Comparative Study Between the Effects of High Doses of Rosuvastatin and Atorvastatin on Ventricular Remodeling in Patients with ST-Segment Elevation Myocardial Infarction

Efficacy and Safety of Rosuvastatin Versus Atorvastatin in High-Risk Chinese Patients with Hypercholesterolemia: a Randomized, Double-Blind, Active-Controlled Study

The Effectiveness and Safety of Intensive Lipid-Lowering with Different Rosuvastatin-Based Regimens in Patients at High Cardiovascular Disease Risk: A Nonblind, Randomized, Controlled Trial

Effect of different dose of atorvastatin on plasma soluble OX40L level in patients with acute coronary syndrome

Meta-analysis Comparing the Effects of Rosuvastatin Versus Atorvastatin on Regression of Coronary Atherosclerotic Plaques